Your browser doesn't support javascript.
loading
Weaning practices in phenylketonuria vary between health professionals in Europe.
Pinto, A; Adams, S; Ahring, K; Allen, H; Almeida, M F; Garcia-Arenas, D; Arslan, N; Assoun, M; Atik Altinok, Y; Barrio-Carreras, D; Belanger Quintana, A; Bernabei, S M; Bontemps, C; Boyle, F; Bruni, G; Bueno-Delgado, M; Caine, G; Carvalho, R; Chrobot, A; Chyz, K; Cochrane, B; Correia, C; Corthouts, K; Daly, A; De Leo, S; Desloovere, A; De Meyer, A; De Theux, A; Didycz, B; Dijsselhof, M E; Dokoupil, K; Drabik, J; Dunlop, C; Eberle-Pelloth, W; Eftring, K; Ekengren, J; Errekalde, I; Evans, S; Foucart, A; Fokkema, L; François, L; French, M; Forssell, E; Gingell, C; Gonçalves, C; Gökmen Özel, H; Grimsley, A; Gugelmo, G; Gyüre, E; Heller, C.
Afiliação
  • Pinto A; Birmingham Women's and Children's Hospital, Birmingham, UK.
  • Adams S; Royal Victoria Infirmary, Newcastle, UK.
  • Ahring K; Department of PKU, Kennedy Centre, Department of Paediatrics and Adolescents Medicine, Copenhagen University Hospital, Glostrup, Denmark.
  • Allen H; Sheffield Children's NHS Foundation Trust, UK.
  • Almeida MF; Centro de Genética Médica, Centro Hospitalar Universitário do Porto (CHP), Porto, Portugal.
  • Garcia-Arenas D; Unit for Multidisciplinary Research in Biomedicine, Abel Salazar Institute of Biomedical Sciences, University of Porto-UMIB/ICBAS/UP, Porto, Portugal.
  • Arslan N; Centro de Referência na área de Doenças Hereditárias do Metabolismo, Centro Hospitalar Universitário do Porto - CHP, Porto, Portugal.
  • Assoun M; Congenital and Metabolic Disease Unit, Gastroenterology, Hepatology and Pediatric Nutrition Unit, Sant Joan de Déu Hospital, Barcelona, Spain.
  • Atik Altinok Y; Division of Pediatric Metabolism and Nutrition, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.
  • Barrio-Carreras D; Hôpital Necker enfants Malades, Centre de référence des maladies héréditaires du métabolisme, Paris, France.
  • Belanger Quintana A; Pediatric Metabolism Department, Ege University Medical Faculty, Izmir, Turkey.
  • Bernabei SM; Servicio de Pediatria, Unidad de Enfermedades Mitocondriales-Metabolicas Hereditarias, Hospital 12 de Octubre, Madrid, Spain.
  • Bontemps C; Servicio de Pediatria, Hospital Ramon y Cajal Madrid, Unidad de Enfermedades Metabolicas, Spain.
  • Boyle F; Division of Artificial Nutrition, Children's Hospital Bambino Gesù, Rome, Italy.
  • Bruni G; CHRU Clocheville Tours, France.
  • Bueno-Delgado M; National Centre for Inherited Metabolic Disorders, Temple Street Children's University Hospital, Italy.
  • Caine G; Meyer Children's hospital, Florence, Italy.
  • Carvalho R; Children's Hospital Virgen del Rocío, Seville, Spain.
  • Chrobot A; Mid Yorks NHS Trust, UK.
  • Chyz K; Hospital Divino Espírito Santo, Ponta Delgada, Portugal.
  • Cochrane B; Children Voievodship Hospital, Bydgoszcz, Poland.
  • Correia C; Institute of Mother and Child, Warsaw, Poland.
  • Corthouts K; Royal Hospital for Children, Glasgow, UK.
  • Daly A; CHLC- Hospital Dona Estefânia, Lisboa, Portugal.
  • De Leo S; University hospital Leuven, Belgium.
  • Desloovere A; Birmingham Women's and Children's Hospital, Birmingham, UK.
  • De Meyer A; Department of Human Neuroscience, Sapienza University of Rome - Policlinico Umberto I of Rome, Italy.
  • De Theux A; University hospital Ghent, Belgium.
  • Didycz B; Center of Metabolic Diseases, University Hospital, Antwerp, Belgium.
  • Dijsselhof ME; IPG (Institut de Pathologie et de Genetique), Charleroi, Belgium.
  • Dokoupil K; University Children's Hospital, Cracow, Poland.
  • Drabik J; AMC Amsterdam/Emma Children's Hospital, Netherlands.
  • Dunlop C; Dr. von Hauner Children's Hospital of the University of Munich, Germany.
  • Eberle-Pelloth W; University Clinical Center in Gdansk, Poland.
  • Eftring K; Royal Hospital for Children Edinburgh, UK.
  • Ekengren J; Universitäts-Kinderklinik Würzburg, Germany.
  • Errekalde I; Queen Silivia's Children's Hospital Gothenburg, Sweden.
  • Evans S; Queen Silivia's Children's Hospital Gothenburg, Sweden.
  • Foucart A; Hospital Universitario de Cruces, Vizcaya, Spain.
  • Fokkema L; Birmingham Women's and Children's Hospital, Birmingham, UK.
  • François L; Cliniques universitaires Saint-Luc, Belgium.
  • French M; UMC Utrecht Wilhelmina Children's Hospital, Netherlands.
  • Forssell E; centre de référence des maladies héréditaires du métabolisme, Hôpital Universitaire Robert-Debré, Paris, France.
  • Gingell C; University Hospitals of Leicester NHS Trust, UK.
  • Gonçalves C; Karolinska University Hospital, Stockholm, Sweden.
  • Gökmen Özel H; Nottingham Children's Hospital, UK.
  • Grimsley A; Hospital Central do Funchal, Portugal.
  • Gugelmo G; Ihsan Dogramaci Children's Hospital, Hacettepe University, Turkey.
  • Gyüre E; Royal Belfast Hospital for Sick Children, Northern Ireland, UK.
  • Heller C; Department of Pediatrics, Inherited Metabolic Diseases Unit, University Hospital of Verona, Italy.
Mol Genet Metab Rep ; 18: 39-44, 2019 Mar.
Article em En | MEDLINE | ID: mdl-30705824
ABSTRACT

BACKGROUND:

In phenylketonuria (PKU), weaning is considered more challenging when compared to feeding healthy infants. The primary aim of weaning is to gradually replace natural protein from breast milk or standard infant formula with solids containing equivalent phenylalanine (Phe). In addition, a Phe-free second stage L-amino acid supplement is usually recommended from around 6 months to replace Phe-free infant formula. Our aim was to assess different weaning approaches used by health professionals across Europe.

METHODS:

A cross sectional questionnaire (survey monkey®) composed of 31 multiple and single choice questions was sent to European colleagues caring for inherited metabolic disorders (IMD). Centres were grouped into geographical regions for analysis.

RESULTS:

Weaning started at 17-26 weeks in 85% (n = 81/95) of centres, >26 weeks in 12% (n = 11/95) and < 17 weeks in 3% (n = 3/95). Infant's showing an interest in solid foods, and their age, were important determinant factors influencing weaning commencement. 51% (n = 48/95) of centres introduced Phe containing foods at 17-26 weeks and 48% (n = 46/95) at >26 weeks. First solids were mainly low Phe vegetables (59%, n = 56/95) and fruit (34%, n = 32/95).A Phe exchange system to allocate dietary Phe was used by 52% (n = 49/95) of centres predominantly from Northern and Southern Europe and 48% (n = 46/95) calculated most Phe containing food sources (all centres in Eastern Europe and the majority from Germany and Austria). Some centres used a combination of both methods.A second stage Phe-free L-amino acid supplement containing a higher protein equivalent was introduced by 41% (n = 39/95) of centres at infant age 26-36 weeks (mainly from Germany, Austria, Northern and Eastern Europe) and 37% (n = 35/95) at infant age > 1y mainly from Southern Europe. 53% (n = 50/95) of centres recommended a second stage Phe-free L-amino acid supplement in a spoonable or semi-solid form.

CONCLUSIONS:

Weaning strategies vary throughout European PKU centres. There is evidence to suggest that different infant weaning strategies may influence longer term adherence to the PKU diet or acceptance of Phe-free L-amino acid supplements; rendering prospective long-term studies important. It is essential to identify an effective weaning strategy that reduces caregiver burden but is associated with acceptable dietary adherence and optimal infant feeding development.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article